Developments in Biotechnology

Research Passions and Information

Group Commander:

Analysis Interests

Improvement biosimilars and tiny particles. Learn of modulators of TDP43 aggregation.

Details of analysis

The Group (BDG) centers on the development of simple and revolutionary technologies when it comes to creation of biosimilars. The goal is to raise the knowledge and capabilities of this pharmaceutical sectors in ICGEB by moving technologies for production and quality control of common biologics in pilot scale for the technologies for erythropoietin (EPO), interferon alpha 2a and b (IFN alpha 2), interferon beta 1b, granulocyte colony exciting element (G-CSF) and Insulin. The group in addition has developed PEGylation technologies in collaboration with the for IFN, GCSF and EPO.

The lab’s procedures could be adapted towards the circumstances current in associate shows with only minimal financial investment required to set-up manufacturing facilities. The transfer among these technologies involves the instruction of experts from pharmaceutical organizations for periods of one to two months. During this time period, they learn the manipulation of recombinant strains, exercise the downstream process and perform quality-control treatments relative to the principles for the .

Over the past couple of years, the Group has actually trained above 78 experts from 19 various ICGEB Member States. These types of from businesses that are now creating biosimilars utilizing our technologies. Not merely tend to be the products in love with the local areas, they successfully participate from the international market.

Present research in group centers on Rapamycin stress development, little molecule chemistry development and innovative chemical adjustment of EPO. Finally, benefiting from a model produced by the regarding TDP43 aggregation observed in clients with amyotrophic horizontal sclerosis we now have put up an investigation project aimed to study the modulators of TDP43 aggregation.

a display screen of compounds are now being tested because of their impact as clearance agents and consequently prospective use within neurodegenerative diseases therapies with initial results showing some compounds capable reduce aggregation by above 50% (shown in Figure).

Current Publications

Menvielle, J.P., Safini, N., Tisminetzky, S.G., Skoko, N. 2012. Twin Role of Dextran Sulfate 5000 Da as Anti-Apoptotic and Pro-Autophagy Agent. Mol Biotechnol. [Epub in front of printing]